Trastuzumab deruxtecan

Generic Name
Trastuzumab deruxtecan
Brand Names
Enhertu
Drug Type
Biotech
Chemical Formula
-
CAS Number
1826843-81-5
Unique Ingredient Identifier
5384HK7574
Background

Trastuzumab deruxtecan is a HER-2 directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of metastatic, unresectable breast cancer. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. Trastuz...

Indication

In the US, trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. It...

Associated Conditions
Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Adenocarcinoma, Metastatic Breast Cancer, Metastatic Breast Cancer With HER2 Positive, Unresectable Breast Cancer, Locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Locally advanced HER2-positive Gastric Adenocarcinoma, Metastatic HER2 Mutant Non-small Cell Lung Cancer, Metastatic HER2-low Breast Cancer, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic HER2-positive Gastric Adenocarcinoma, Unresectable HER2 Mutant Non-small Cell Lung Cancer, Unresectable HER2-low Breast Cancer, Unresectable HER2/Neu-positive Breast Cancer
Associated Therapies
-
Clinical Trials
Related News

HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

First Posted Date
2024-04-26
Last Posted Date
2024-10-03
Lead Sponsor
AstraZeneca
Target Recruit Count
75
Registration Number
NCT06386263
Locations
🇨🇦

Research Site, Oakville, Ontario, Canada

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

First Posted Date
2024-04-15
Last Posted Date
2024-12-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
48
Registration Number
NCT06364410
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

Phase 1
Not yet recruiting
Conditions
Breast Cancer
Interventions
Drug: Anlotinib
Drug: Trastuzumab deruxtecan
First Posted Date
2024-03-26
Last Posted Date
2024-03-26
Lead Sponsor
Fudan University
Target Recruit Count
42
Registration Number
NCT06331169
Locations
🇨🇳

Jian Zhang, Shanghai, Shanghai, China

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

First Posted Date
2024-03-25
Last Posted Date
2024-03-25
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
120
Registration Number
NCT06328387
Locations
🇨🇳

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

First Posted Date
2024-03-21
Last Posted Date
2024-11-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
240
Registration Number
NCT06324357
Locations
🇧🇪

UZ Leuven, Leuven, Belgium

🇺🇸

Valkyrie Clinical Trials, Los Angeles, California, United States

🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

and more 4 locations

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

First Posted Date
2024-03-15
Last Posted Date
2024-12-19
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
500
Registration Number
NCT06311214

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

First Posted Date
2024-02-22
Last Posted Date
2024-11-22
Lead Sponsor
AstraZeneca
Target Recruit Count
175
Registration Number
NCT06271837
Locations
🇨🇳

Research Site, Zhengzhou, China

Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases

Phase 2
Not yet recruiting
Conditions
Non Small Cell Lung Cancer
Interventions
Drug: Trastuzumab deruxtecan
First Posted Date
2024-02-09
Last Posted Date
2024-02-09
Lead Sponsor
Yonsei University
Target Recruit Count
27
Registration Number
NCT06250777
Locations
🇰🇷

Yonsei University Health system, Severance Hospital, Seoul, Korea, Republic of

Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil

Terminated
Conditions
Breast Cancer
Interventions
Drug: Trastuzumab deruxtecan
First Posted Date
2024-01-30
Last Posted Date
2024-10-01
Lead Sponsor
AstraZeneca
Target Recruit Count
2
Registration Number
NCT06231693
Locations
🇧🇷

Research Site, São Paulo, Brazil

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

First Posted Date
2024-01-18
Last Posted Date
2024-10-02
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
800
Registration Number
NCT06210776
Locations
🇨🇳

Peking University First Hospital, Beijing, China

🇨🇳

China-Japan Friendship Hospital, Beijing, China

🇨🇳

Peking University Shougang Hospital, Beijing, China

and more 35 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy